Open AccessTreatment Outcomes Stratified by Baseline Immunological Status among Young Children Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Resource-Limited Settings
Author(s) -
D. O’Brien,
Delphine Sauvageot,
David M. Olson,
Melody Schaeffer,
P.A. Humblet,
M. Pudjades,
Tom Ellman,
Rony Zachariah,
Elisabeth Szumilin,
Line Arnould,
Timothy D. Read
Publication year - 2007
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/513433
Subject(s) - medicine , confidence interval , antiretroviral therapy , reverse transcriptase inhibitor , reverse transcriptase , human immunodeficiency virus (hiv) , sida , immunology , viral disease , viral load , biology , polymerase chain reaction , biochemistry , gene
A study of 568 children aged <5 years who commenced nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings revealed good early outcomes. After 12 months of antiretroviral therapy, survival probability was 0.89 (95% confidence interval, 0.86-0.92), with no significant difference among children stratified on the basis of baseline immunological levels; 62% attained a CD4 cell percentage >25%, and 7% continued to have a CD4 cell percentage <15%.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom